Search

Your search keyword '"Agathe Dubuisson"' showing total 5 results
Start Over Author "Agathe Dubuisson" Publisher american association for cancer research (aacr)
5 results on '"Agathe Dubuisson"'

1. Supplementary Figure from The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals

Author

Laurence Zitvogel, Lisa Derosa, Markus Maeurer, Bernard La Scola, Guido Kroemer, Odile Launay, Emma Guttman-Yassky, Florence Fenollar, Sophie Caillat-Zucman, Mathieu F. Chevalier, Juliette Villemonteix, Fabrice André, Miriam Merad, Jean-Charles Soria, Jean-Yves Blay, Frank Griscelli, Aurélien Marabelle, Florian Scotté, Mansouria Merad, Jean-Philippe Spano, Bertrand Gachot, Eric Deutsch, Nathalie Droin, Marc Deloger, Pernelle Lavaud, Emeline Colomba, Fanny Pommeret, Emmanuelle Gallois, Caroline Pradon, Yeriel Estrada, Benjamin Ungar, Alexandre Trubert, Fabrice Barlesi, Guy Gorochov, Makoto Miyara, Abdelhakim Ahmed-Belkacem, Lydia Meziani, Nadine Benhamouda, Eric Tartour, Pierre Ly, Caroline Flament, Eugenie Pizzato, Safae Terrisse, François-Xavier Danlos, Marianne Gazzano, Benoît Kloeckner, Alice Bernard-Tessier, Ariane Laparra, Joana R. Lérias, Luigi Cerbone, Marion Picard, Camille Bigenwald, Roxanne Birebent, Gladys Ferrere, Arthur Geraud, Agathe Dubuisson, Cléa Melenotte, Cassandra Thelemaque, Eric de Sousa, Carolina Alves Costa Silva, Damien Drubay, Marine Mazzenga, Agathe Carrier, Yacine Haddad, Anne-Gaëlle Goubet, Imran Lahmar, and Jean-Eudes Fahrner

Abstract

Supplementary Figure from The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals

Published
2023

2. Supplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

Author

Yohann Loriot, Laurence Zitvogel, Jean-Yves Scoazec, Guido Kroemer, Miriam Merad, Fabrice Andre, Benjamin Besse, Michiel S. Van Der Heijden, Nick Van Dijk, Jeroen Van Dorp, Aurélien Marabelle, Lisa Derosa, Gwénaël Le Teuff, Florent Ginhoux, Mathieu Rouanne, Jacques Fieschi, Yves Allory, Camelia Radulescu, Etienne Rouleau, Romain Daillere, Adeline Mallet, Maryse Moya-Nilges, Nadège Cayet, Ivo Gomperts Boneca, Shaima Belhechmi, Baptiste Archambaud, Thibault Raoult, Aymeric Silvin, Kevin Mulder, Garett Dunsmore, François-Xavier Danlos, Camille Bleriot, Jacques Bou Khalil, Gabriel Haddad, Caroline Davin, Mounia Filahi, Thomas Sbarrato, Allan Sauvat, Nicolas Signolle, Virginie Marty, Pierre Ly, Caroline Flament, Marine Mazzenga, Agathe Dubuisson, Idir Ouzaid, Evanguelos Xylinas, Morgan Roupret, Luca Campedel, Carole Helissey, Gwenaelle Gravis, Géraldine Pignot, François Audenet, Constance Thibault, Cédric Lebacle, Cassandra Thelemaque, Maxime Descartes Mbogning-Fonkou, Marianne Gazzano, Isabelle Peguillet, Carolina Alves Costa Silva, Leonardo Lordello, and Anne-Gaëlle Goubet

Abstract

Supplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

Published
2023

3. Supplementary Data from The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals

Author

Laurence Zitvogel, Lisa Derosa, Markus Maeurer, Bernard La Scola, Guido Kroemer, Odile Launay, Emma Guttman-Yassky, Florence Fenollar, Sophie Caillat-Zucman, Mathieu F. Chevalier, Juliette Villemonteix, Fabrice André, Miriam Merad, Jean-Charles Soria, Jean-Yves Blay, Frank Griscelli, Aurélien Marabelle, Florian Scotté, Mansouria Merad, Jean-Philippe Spano, Bertrand Gachot, Eric Deutsch, Nathalie Droin, Marc Deloger, Pernelle Lavaud, Emeline Colomba, Fanny Pommeret, Emmanuelle Gallois, Caroline Pradon, Yeriel Estrada, Benjamin Ungar, Alexandre Trubert, Fabrice Barlesi, Guy Gorochov, Makoto Miyara, Abdelhakim Ahmed-Belkacem, Lydia Meziani, Nadine Benhamouda, Eric Tartour, Pierre Ly, Caroline Flament, Eugenie Pizzato, Safae Terrisse, François-Xavier Danlos, Marianne Gazzano, Benoît Kloeckner, Alice Bernard-Tessier, Ariane Laparra, Joana R. Lérias, Luigi Cerbone, Marion Picard, Camille Bigenwald, Roxanne Birebent, Gladys Ferrere, Arthur Geraud, Agathe Dubuisson, Cléa Melenotte, Cassandra Thelemaque, Eric de Sousa, Carolina Alves Costa Silva, Damien Drubay, Marine Mazzenga, Agathe Carrier, Yacine Haddad, Anne-Gaëlle Goubet, Imran Lahmar, and Jean-Eudes Fahrner

Abstract

Supplementary Data from The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals

Published
2023

4. Data from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

Author

Yohann Loriot, Laurence Zitvogel, Jean-Yves Scoazec, Guido Kroemer, Miriam Merad, Fabrice Andre, Benjamin Besse, Michiel S. Van Der Heijden, Nick Van Dijk, Jeroen Van Dorp, Aurélien Marabelle, Lisa Derosa, Gwénaël Le Teuff, Florent Ginhoux, Mathieu Rouanne, Jacques Fieschi, Yves Allory, Camelia Radulescu, Etienne Rouleau, Romain Daillere, Adeline Mallet, Maryse Moya-Nilges, Nadège Cayet, Ivo Gomperts Boneca, Shaima Belhechmi, Baptiste Archambaud, Thibault Raoult, Aymeric Silvin, Kevin Mulder, Garett Dunsmore, François-Xavier Danlos, Camille Bleriot, Jacques Bou Khalil, Gabriel Haddad, Caroline Davin, Mounia Filahi, Thomas Sbarrato, Allan Sauvat, Nicolas Signolle, Virginie Marty, Pierre Ly, Caroline Flament, Marine Mazzenga, Agathe Dubuisson, Idir Ouzaid, Evanguelos Xylinas, Morgan Roupret, Luca Campedel, Carole Helissey, Gwenaelle Gravis, Géraldine Pignot, François Audenet, Constance Thibault, Cédric Lebacle, Cassandra Thelemaque, Maxime Descartes Mbogning-Fonkou, Marianne Gazzano, Isabelle Peguillet, Carolina Alves Costa Silva, Leonardo Lordello, and Anne-Gaëlle Goubet

Abstract

Biomarkers guiding the neoadjuvant use of immune-checkpoint blockers (ICB) are needed for patients with localized muscle-invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression at baseline and the induction of tertiary lymphoid structures after pembrolizumab. Blood central memory TFH accumulated in tumors where they produce CXCL13, a chemokine found in the plasma of responders only. IgG4+CD38+ TFH residing in bladder tissues correlated with clinical benefit. Finally, TFH and IgG directed against urothelium-invasive Escherichia coli dictated clinical responses to pembrolizumab in three independent cohorts. The links between tumor infection and success of ICB immunomodulation should be prospectively assessed at a larger scale.Significance:In patients with bladder cancer treated with neoadjuvant pembrolizumab, E. coli–specific CXCL13 producing TFH and IgG constitute biomarkers that predict clinical benefit. Beyond its role as a biomarker, such immune responses against E. coli might be harnessed for future therapeutic strategies.This article is highlighted in the In This Issue feature, p. 2221

Published
2023

5. Data from The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals

Author

Laurence Zitvogel, Lisa Derosa, Markus Maeurer, Bernard La Scola, Guido Kroemer, Odile Launay, Emma Guttman-Yassky, Florence Fenollar, Sophie Caillat-Zucman, Mathieu F. Chevalier, Juliette Villemonteix, Fabrice André, Miriam Merad, Jean-Charles Soria, Jean-Yves Blay, Frank Griscelli, Aurélien Marabelle, Florian Scotté, Mansouria Merad, Jean-Philippe Spano, Bertrand Gachot, Eric Deutsch, Nathalie Droin, Marc Deloger, Pernelle Lavaud, Emeline Colomba, Fanny Pommeret, Emmanuelle Gallois, Caroline Pradon, Yeriel Estrada, Benjamin Ungar, Alexandre Trubert, Fabrice Barlesi, Guy Gorochov, Makoto Miyara, Abdelhakim Ahmed-Belkacem, Lydia Meziani, Nadine Benhamouda, Eric Tartour, Pierre Ly, Caroline Flament, Eugenie Pizzato, Safae Terrisse, François-Xavier Danlos, Marianne Gazzano, Benoît Kloeckner, Alice Bernard-Tessier, Ariane Laparra, Joana R. Lérias, Luigi Cerbone, Marion Picard, Camille Bigenwald, Roxanne Birebent, Gladys Ferrere, Arthur Geraud, Agathe Dubuisson, Cléa Melenotte, Cassandra Thelemaque, Eric de Sousa, Carolina Alves Costa Silva, Damien Drubay, Marine Mazzenga, Agathe Carrier, Yacine Haddad, Anne-Gaëlle Goubet, Imran Lahmar, and Jean-Eudes Fahrner

Abstract

Vaccination against coronavirus disease 2019 (COVID-19) relies on the in-depth understanding of protective immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We characterized the polarity and specificity of memory T cells directed against SARS-CoV-2 viral lysates and peptides to determine correlates with spontaneous, virus-elicited, or vaccine-induced protection against COVID-19 in disease-free and cancer-bearing individuals. A disbalance between type 1 and 2 cytokine release was associated with high susceptibility to COVID-19. Individuals susceptible to infection exhibited a specific deficit in the T helper 1/T cytotoxic 1 (Th1/Tc1) peptide repertoire affecting the receptor binding domain of the spike protein (S1-RBD), a hotspot of viral mutations. Current vaccines triggered Th1/Tc1 responses in only a fraction of all subject categories, more effectively against the original sequence of S1-RBD than that from viral variants. We speculate that the next generation of vaccines should elicit Th1/Tc1 T-cell responses against the S1-RBD domain of emerging viral variants.Significance:This study prospectively analyzed virus-specific T-cell correlates of protection against COVID-19 in healthy and cancer-bearing individuals. A disbalance between Th1/Th2 recall responses conferred susceptibility to COVID-19 in both populations, coinciding with selective defects in Th1 recognition of the receptor binding domain of spike.See related commentary by McGary and Vardhana, p. 892.This article is highlighted in the In This Issue feature, p. 873

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results